Table 1. Characteristics of patients who received ADT, stratified by FSH.

Demographic variables	FSH		P value
	Low/normal (≤8 UI/mL) (N=878)	High (>8 UI/mL) (N=661)
Age at ADT (years)	73 [68, 79]	76 [70, 83]	<0.0011
Year of ADT start	2009 [2004, 2013]	2007 [2004, 2012]	0.0271
Race, n [%]			0.1162
Black	307 [35]	195 [30]
White	473 [54]	377 [57]
Other	40 [5]	34 [5]
Unknown	58 [7]	55 [8]
BMI at ADT (kg/m2)	30.1 (26.3, 34.2)	29.1 (25.8, 33.2)	0.0041
CCI at ADT			0.1022
0–2	252 [29]	165 [25]
3+	626 [71]	496 [75]
Primary XRT or RP	111 [13]	98 [15]	0.2162
Grade group			0.3472
1	201 [23]	144 [22]
2–3	286 [33]	201 [30]
4–5	275 [31]	208 [31]
Unknown	116 [13]	108 [16]
PSA at ADT (ng/mL)	6.6 (2.5, 13.9)	6.5 (2.4, 13.8)	0.8071
Testosterone pre-ADT			0.6222
<30 ng/mL	183 [21]	136 [21]
30–299 ng/mL	203 [23]	138 [21]
≥300 ng/mL	182 [21]	152 [23]
Missing	310 [35]	235 [36]
Chemo before ADT			0.0532
Never	753 [86]	579 [88]
Before ADT	18 [2]	22 [3]
After ADT	107 [12]	60 [9]
Months from FSH to ADT	8.4 (3.0, 15.9)	7.9 (3.2, 14.6)	0.1991
CRPC	231 [26]	177 [27]	0.8372
Dead	381 [43]	337 [51]	0.0032

Data are shown as median (Q1, Q3) or n [%]. ¹, Wilcoxon; ², Chi-Square. ADT, androgen deprivation therapy; FSH, follicle-stimulating hormone; BMI, body mass index; CCI, Charlson Comorbidity Index; XRT, radiation therapy; RP, radical prostatectomy; PSA, prostatic-specific antigen; CRPC, castration-resistant prostate cancer.